Annovis Bio to Present at the June 2020 Virtual Summer Investor Summit
June 09 2020 - 06:45AM
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease (AD), Parkinson’s
disease (PD) and other neurodegenerative diseases, today
announced that CEO Maria Maccecchini, Ph.D. and CFO Jeff
McGroarty, MBA, CPA, will give a virtual corporate presentation at
the June 2020 Virtual Summer Investor Summit taking place online
from June 9 to 12, 2020.
Annovis Bio’s presentation will be held on Wednesday, June 10,
2020 at 10:55 a.m. ET, followed by a live Q&A session.
Investors can register for and access the live webcast at:
https://www.webcaster4.com/Webcast/Page/2038/35035.
Dr. Maccecchini and Mr. McGroarty will also be
available for one-on-one meetings online. To register for the
Virtual Investor Summit, visit:
https://virtual-summer-summit.events.issuerdirect.com/signup
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc.
(Annovis) is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s
disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe
that we are the only company developing a drug for AD, PD and AD-DS
that inhibits more than one neurotoxic protein and, thereby,
improves the information highway of the nerve cell, known as axonal
transport. When this information flow is impaired, the nerve cell
gets sick and dies. We expect our treatment to improve memory loss
and dementia associated with AD and AD-DS, as well as body and
brain function in PD. We have an ongoing Phase 2a study in AD
patients and plan to commence a second Phase 2a study in PD and AD
patients. For more information on Annovis, please visit the
company’s website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast” or other similar words, and
include, without limitation, statements regarding the timing,
effectiveness and anticipated results of ANVS401 clinical trials
and the approval of any allowances or additional patents.
Forward-looking statements are based on Annovis Bio, Inc.’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended
December 31, 2019 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Annovis Bio, Inc.
undertakes no duty to update such information except as required
under applicable law.
Investor Relations:
Dave Gentry, CEO RedChip Companies Inc. 407-491-4498
Dave@redchip.com
SOURCE: Annovis Bio Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Mar 2023 to Mar 2024